Classification of R1 resections for pancreatic cancer: The prognostic relevance of tumour involvement within 1 mm of a resection margin

Histopathology

Volumn 55, Issue 3, 2009, Pages 277-283

  Campbell, Fiona ^a,b   Smith, Richard A ^a   Whelan, Philip ^a   Sutton, Robert ^a   Raraty, Michael ^a   Neoptolemos, John P ^a   Ghaneh, Paula ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Pancreatic cancer; Prognosis; Resection margin

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROGNOSIS;

AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NORWAY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; SURVIVAL RATE;

EID: 69549108342     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03376.x     Document Type: Article

References (21)

1. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Current standards of surgery for pancreatic cancer. Br. J. Surg. 2004 91 1410 1427.
2. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004 350 1200 1210.
3. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007 297 267 277.
4. Benassi G, Mastrorilli M, Quarto G et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of pancreas. J. Surg. Oncol. 2000 73 212 218.
5. Han S, Jang J, Kim S, Kim WH, Lee KU, Park YH. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006 32 271 275.
6. Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 2006 32 37 43.
7. Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann. Surg. 2007 246 52 60.
8. Winter JM, Cameron JL, Campbell KA et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J. Gastrointest. Surg. 2006 10 1199 1210.
9. Esposito I, Kleeff J, Bergmann F et al. Most pancreatic cancer resections are R1 resections. Ann. Surg. Oncol. 2008 15 1651 1660.
10. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br. J. Surg. 2006 93 1232 1237.
11. Campbell F, Bennett M, Foulis AJ. Minimum dataset for histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma. London : Royal College of Pathologists, 2002. Available at http://www.rcpath.org. Last accessed on 27 October 2008.
12. Pawlik TM, Gleisner AL, Cameron JL et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007 141 610 618.
13. Bassi C, Stocken DD, Olah A et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig. Surg. 2005 22 353 363.
14. Jarufe NP, Coldham C, Mayer AD, Mirza DF, Buckels JAC, Bramhall SR. Favourable prognostic factors in a large UK experience of adenocarcinoma of the head of the pancreas and periampullary region. Dig. Surg. 2004 21 202 209.
15. Butturini G, Stocken DD, Wente MN et al Pancreatic Cancer Meta-Analysis Group. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch. Surg. 2008 143 75 83.
16. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993 72 2118 2223.
17. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer: local or hepatic? Hepatogastroenterology 1993 40 384 387.
18. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J. Surg. 1997 21 195 200. (Pubitemid 27053441)
19. Nagakawa T, Nagamori M, Futakami F et al. Results of extensive surgery for pancreatic carcinoma. Cancer 1996 77 640 645.
20. Neoptolemos JP, Stocken DD, Dunn JA et al European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. 2001 234 758 768.
21. Neoptolemos JP, Buchler M, Stocken DD et al. ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J. Clin. Oncol. 2009 27 18 suppl (abstr LBA4505).